MarginsXMarginsX
Home › Markets › Health Care › TWST

Twist Bioscience Corporation (TWST)

TWST trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$105.04
-5.88% on the day
Market cap
$7.0B
Mid cap
Revenue · 2025
$376.6M
+20.3% on 2024
Net income · 2025
-$77.7M
-20.6% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-09-30, https://www.sec.gov/Archives/edgar/data/1581280/000158128025000025/0001581280-25-000025-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-09-30.

Profile

FieldValue
TickerTWST on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2018
SEC CIK0001581280
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2025

LineValue
Revenue$376.6M
Net income-$77.7M
Operating income-$136.3M
Net margin-20.6%
Operating margin-36.2%
Revenue growth+20.3%
Cash$183.0M
Total assets$641.9M
P/E (computed)Net income was not positive
P/S (computed)18.5×

Warning signs

Cash runway
26.6 months
$117.4M cash at June 30, 2026
Share count, 1 year
+3.9%
2025-07-31 to 2026-07-29 · +9.3% over 3 years
Going-concern doubt
No
10-Q filed August 3, 2026
Insider net buying, 12 months
-$131.4M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-08-03
Cash and burn$117.4M cash; operating cash flow -$13.3M a quarter.Report 2026-06-30
Shares outstanding62,707,424 (2026-07-29); 60,360,925 a year earlier; 57,396,131 three years earlier.Cover page 2026-07-29
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2026-08-05
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, San Mateo, California, United StatesPCAOB Form AP 2025-12-05
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $131.4M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-06-30
$118.4M-$35.1M$1.1M$117.4MNo debt tags$431.8M10-Q 2026-08-03
Q2 2026
2026-03-31
$110.7M-$44.0M-$17.6M$122.7MNo debt tags$409.5M10-Q 2026-05-04
Q1 2026
2025-12-31
$103.7M-$30.5M-$24.8M$148.6MNo debt tags$391.6M10-Q/A 2026-02-26
Q4 2025
2025-09-30
$99.0M-$27.1M-$11.8M$183.0MNo debt tags$376.6M10-K 2025-11-17
Q3 2025
2025-06-30
$96.1M$20.4M-$1.4M$201.4MNo debt tags$362.3M10-Q 2026-08-03
Q2 2025
2025-03-31
$92.8M-$39.3M-$13.0M$210.4MNo debt tags$347.7M10-Q 2026-05-04
Q1 2025
2024-12-31
$88.7M-$31.6M-$21.4M$221.4MNo debt tags$330.2M10-Q/A 2026-02-26
Q4 2024
2024-09-30
$84.7M-$34.7M-$15.3M$226.3MNo debt tags$313.0M10-K 2025-11-17

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B72026-08-19
Latest annual report10-K2026-11-16
Latest quarterly / interim10-Q2026-08-03
Latest current report8-K2026-11-12
Latest proxyDEF 14A2026-01-06

Source: SEC EDGAR submissions feed, 1,017 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-7.6%
1 month-26.3%
3 months-10.9%
Year to date+251.8%
1 year+273.2%
From 52-week high-45.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
IMVTImmunovant Inc.$33.28-2.63%$6.9B
KODKodiak Sciences Inc$100.73-9.41%$6.6B
CGONCG Oncology Inc.$84.78+13.95%$7.6B
IBRXImmunityBio Inc.$5.98-0.66%$6.4B
KRYSKrystal Biotech Inc.$297.90-2.40%$8.8B
SRRKScholar Rock Holding Corporation$44.54+3.09%$5.4B
PCVXVaxcyte Inc.$61.61-2.78%$9.8B
QGENQiagen N.V. Common Shares$49.81-0.16%$10.3B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier